4oj4 - Revision history

OCA at 12:40, 1 March 2024

OCA — Fri, 01 Mar 2024 12:40:07 GMT

←Older revision		Revision as of 12:40, 1 March 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4oj4]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OJ4 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4OJ4 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4oj4]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OJ4 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4OJ4 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=DIF:2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC+ACID'>DIF</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.3Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=DIF:2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC+ACID'>DIF</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4oj4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oj4 OCA], [https://pdbe.org/4oj4 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4oj4 RCSB], [https://www.ebi.ac.uk/pdbsum/4oj4 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4oj4 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4oj4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oj4 OCA], [https://pdbe.org/4oj4 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4oj4 RCSB], [https://www.ebi.ac.uk/pdbsum/4oj4 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4oj4 ProSAT]</span></td></tr>
	</table>		</table>

OCA at 07:28, 25 January 2023

OCA — Wed, 25 Jan 2023 07:28:44 GMT

←Older revision		Revision as of 07:28, 25 January 2023
Line 3:		Line 3:
	<StructureSection load='4oj4' size='340' side='right'caption='[[4oj4]], [[Resolution\|resolution]] 2.30Å' scene=''>		<StructureSection load='4oj4' size='340' side='right'caption='[[4oj4]], [[Resolution\|resolution]] 2.30Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4oj4]] is a 1 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OJ4 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4OJ4 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4oj4]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OJ4 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4OJ4 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=DIF:2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC+ACID'>DIF</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=DIF:2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC+ACID'>DIF</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1prg\|1prg]], [[3sz1\|3sz1]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4oj4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oj4 OCA], [https://pdbe.org/4oj4 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4oj4 RCSB], [https://www.ebi.ac.uk/pdbsum/4oj4 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4oj4 ProSAT]</span></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PPARG, NR1C3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4oj4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oj4 OCA], [~~http~~://pdbe.org/4oj4 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4oj4 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4oj4 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4oj4 ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:[~~http~~://omim.org/entry/601665 601665]]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.<ref>PMID:9753710</ref> Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:[~~http~~://omim.org/entry/604367 604367]]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.<ref>PMID:12453919</ref> <ref>PMID:11788685</ref> Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:[~~http~~://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.	+	[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN] Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:[https://omim.org/entry/601665 601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.<ref>PMID:9753710</ref> Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:[https://omim.org/entry/604367 604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.<ref>PMID:12453919</ref> <ref>PMID:11788685</ref> Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:[https://omim.org/entry/137800 137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>	+	[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>

	==See Also==		==See Also==
-	*[[Peroxisome ~~Proliferator~~-~~Activated Receptors~~\|Peroxisome ~~Proliferator~~-~~Activated Receptors~~]]	+	*[[Peroxisome proliferator-activated receptor 3D structures\|Peroxisome proliferator-activated receptor 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Polikarpov, I]]	+	[[Category: Polikarpov I]]
-	[[Category: Puhl~~, A C~~]]	+	[[Category: Puhl AC]]
-	[[Category: Webb, P]]	+	[[Category: Webb P]]
-	~~[[Category: Mainly alpha helix]]~~	+
-	~~[[Category: Nuclear receptor]]~~	+
-	~~[[Category: Rxr]]~~	+
-	~~[[Category: Transcription]]~~	+
-	~~[[Category: Transcription factor~~]]	+

OCA at 07:38, 17 April 2019

OCA — Wed, 17 Apr 2019 07:38:52 GMT

←Older revision		Revision as of 07:38, 17 April 2019
Line 1:		Line 1:

	==Crystal structure of V290M PPARgamma mutant in complex with diclofenac==		==Crystal structure of V290M PPARgamma mutant in complex with diclofenac==
-	<StructureSection load='4oj4' size='340' side='right' caption='[[4oj4]], [[Resolution\|resolution]] 2.30Å' scene=''>	+	<StructureSection load='4oj4' size='340' side='right'caption='[[4oj4]], [[Resolution\|resolution]] 2.30Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4oj4]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OJ4 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OJ4 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4oj4]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OJ4 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OJ4 FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=DIF:2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC+ACID'>DIF</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=DIF:2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC+ACID'>DIF</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1prg\|1prg]], [[3sz1\|3sz1]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1prg\|1prg]], [[3sz1\|3sz1]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PPARG, NR1C3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4oj4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oj4 OCA], [http://pdbe.org/4oj4 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4oj4 RCSB], [http://www.ebi.ac.uk/pdbsum/4oj4 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4oj4 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4oj4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oj4 OCA], [http://pdbe.org/4oj4 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4oj4 RCSB], [http://www.ebi.ac.uk/pdbsum/4oj4 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4oj4 ProSAT]</span></td></tr>
	</table>		</table>
Line 12:		Line 13:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>		[[http://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>
		+
		+	==See Also==
		+	*[[Peroxisome Proliferator-Activated Receptors\|Peroxisome Proliferator-Activated Receptors]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Polikarpov, I]]		[[Category: Polikarpov, I]]
	[[Category: Puhl, A C]]		[[Category: Puhl, A C]]

OCA at 10:59, 11 August 2016

OCA — Thu, 11 Aug 2016 10:59:31 GMT

←Older revision		Revision as of 10:59, 11 August 2016
Line 1:		Line 1:
		+
	==Crystal structure of V290M PPARgamma mutant in complex with diclofenac==		==Crystal structure of V290M PPARgamma mutant in complex with diclofenac==
	<StructureSection load='4oj4' size='340' side='right' caption='[[4oj4]], [[Resolution\|resolution]] 2.30Å' scene=''>		<StructureSection load='4oj4' size='340' side='right' caption='[[4oj4]], [[Resolution\|resolution]] 2.30Å' scene=''>
Line 5:		Line 6:
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=DIF:2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC+ACID'>DIF</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=DIF:2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC+ACID'>DIF</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1prg\|1prg]], [[3sz1\|3sz1]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1prg\|1prg]], [[3sz1\|3sz1]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4oj4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oj4 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4oj4 RCSB], [http://www.ebi.ac.uk/pdbsum/4oj4 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4oj4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oj4 OCA], [http://pdbe.org/4oj4 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4oj4 RCSB], [http://www.ebi.ac.uk/pdbsum/4oj4 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4oj4 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==

OCA at 15:55, 7 February 2015

OCA — Sat, 07 Feb 2015 15:55:46 GMT

←Older revision		Revision as of 15:55, 7 February 2015
Line 1:		Line 1:
-	'''~~Unreleased structure~~'''	+	==Crystal structure of V290M PPARgamma mutant in complex with diclofenac==
-		+	<StructureSection load='4oj4' size='340' side='right' caption='[[4oj4]], [[Resolution\|resolution]] 2.30Å' scene=''>
-	~~The entry~~ 4oj4 is ~~ON HOLD until Paper Publication~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[4oj4]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OJ4 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OJ4 FirstGlance]. <br>
-	~~Authors~~: ~~Puhl~~, A.C., ~~Webb~~, P., ~~Polikarpov, I~~.	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=DIF:2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC+ACID'>DIF</scene></td></tr>
-		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1prg\|1prg]], [[3sz1\|3sz1]]</td></tr>
-	~~Description~~: ~~Crystal structure~~ of ~~V290M PPARgamma mutant~~ in ~~complex~~ with ~~diclofenac~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4oj4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oj4 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4oj4 RCSB], [http://www.ebi.ac.uk/pdbsum/4oj4 PDBsum]</span></td></tr>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	</table>
-	[[~~Category~~: ~~Webb, P~~]]	+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:[http://omim.org/entry/601665 601665]]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.<ref>PMID:9753710</ref> Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:[http://omim.org/entry/604367 604367]]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.<ref>PMID:12453919</ref> <ref>PMID:11788685</ref> Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:[http://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
	[[Category: Polikarpov, I]]		[[Category: Polikarpov, I]]
-	[[Category: Puhl, A.C]]	+	[[Category: Puhl, A C]]
		+	[[Category: Webb, P]]
		+	[[Category: Mainly alpha helix]]
		+	[[Category: Nuclear receptor]]
		+	[[Category: Rxr]]
		+	[[Category: Transcription]]
		+	[[Category: Transcription factor]]

OCA at 14:26, 24 December 2014

OCA — Wed, 24 Dec 2014 14:26:00 GMT

←Older revision		Revision as of 14:26, 24 December 2014
Line 6:		Line 6:

	Description: Crystal structure of V290M PPARgamma mutant in complex with diclofenac		Description: Crystal structure of V290M PPARgamma mutant in complex with diclofenac
		+	[[Category: Unreleased Structures]]
		+	[[Category: Webb, P]]
		+	[[Category: Polikarpov, I]]
		+	[[Category: Puhl, A.C]]

OCA at 12:15, 12 March 2014

OCA — Wed, 12 Mar 2014 12:15:44 GMT

←Older revision		Revision as of 12:15, 12 March 2014
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4oj4 is ON HOLD	+	The entry 4oj4 is ON HOLD until Paper Publication

	Authors: Puhl, A.C., Webb, P., Polikarpov, I.		Authors: Puhl, A.C., Webb, P., Polikarpov, I.

	Description: Crystal structure of V290M PPARgamma mutant in complex with diclofenac		Description: Crystal structure of V290M PPARgamma mutant in complex with diclofenac

OCA: Protected "4oj4" [edit=sysop:move=sysop]

OCA — Wed, 29 Jan 2014 07:10:35 GMT

Protected "4oj4" [edit=sysop:move=sysop]

←Older revision

Revision as of 07:10, 29 January 2014

OCA: New page: '''Unreleased structure''' The entry 4oj4 is ON HOLD Authors: Puhl, A.C., Webb, P., Polikarpov, I. Description: Crystal structure of V290M PPARgamma mutant in complex with diclofenac

OCA — Wed, 29 Jan 2014 07:10:34 GMT

New page: '''Unreleased structure''' The entry 4oj4 is ON HOLD Authors: Puhl, A.C., Webb, P., Polikarpov, I. Description: Crystal structure of V290M PPARgamma mutant in complex with diclofenac

New page

'''Unreleased structure'''

The entry 4oj4 is ON HOLD

Authors: Puhl, A.C., Webb, P., Polikarpov, I.

Description: Crystal structure of V290M PPARgamma mutant in complex with diclofenac